Neurocrine Biosciences’ Ingrezza Shows 94% Clinical Response in 48-Week TD Study
NBIX•New 48-week KINECT 4 post-hoc data show 94% of tardive dyskinesia patients treated with Ingrezza achieved symptomatic remission or ≥30% reduction in AIMS score, including 59% reaching stringent remission. A retrospective analysis of 176,000 Medicare patients found 90% had hepatic risk factors, highlighting Ingrezza’s unique approved dosing in hepatic impairment.
1. KINECT 4 Post-Hoc Efficacy Results
New post-hoc analysis of the 48-week KINECT 4 trial showed that 94% of adults with tardive dyskinesia treated with Ingrezza achieved either stringent symptomatic remission or a clinically meaningful response (≥30% AIMS score reduction). Among patients not meeting the remission threshold, 86% reached ≥30% reduction and 67% reached ≥50%, reinforcing broad treatment benefit.
2. Hepatic Risk Factor Analysis and Dosing Advantage
A retrospective Medicare claims analysis of over 176,000 newly diagnosed tardive dyskinesia patients revealed that 90% had at least one hepatic risk factor and 44% had three or more. These findings underscore the need to consider liver health in treatment decisions and highlight Ingrezza’s unique approved dosing options for patients with hepatic impairment.
